Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indoleamine 2,3-dioxygenase siRNA cancer vaccine
- Development stage
- Preclinical
- Lead developer
- ToleroTech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Topical
01
Overview
The indoleamine 2,3-dioxygenase (IDO) siRNA cancer vaccine is a preclinical-stage therapeutic developed by ToleroTech in collaboration with Bio-Matrix Scientific Group. This vaccine utilizes small interfering RNA (siRNA) to silence the expression of IDO, an immunosuppressive enzyme frequently overexpressed in the tumor microenvironment. IDO promotes immune tolerance by depleting tryptophan and producing kynurenine, which inhibits T-cell proliferation and activation. By silencing IDO, the vaccine is designed to enhance anti-tumor immune responses, specifically for the treatment of melanoma. ToleroTech, the developer, is an archived biotechnology company formerly based in London, Ontario.
- Other names
- IDO siRNA cancer vaccineIDO siRNA vaccinesiRNA silencing of IDOindoleamine 2,3-dioxygenase small interfering RNA cancer vaccine
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on indoleamine 2,3-dioxygenase siRNA cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indoleamine 2,3-dioxygenase siRNA cancer vaccine.